JAMES N. BUTERA M.D.
Prescription History 1790797538
Internal Medicine - Hematology & Oncology in Providence, RI

NPI Status: Active since August 12, 2006

Contact Information

593 EDDY ST
APC 138
PROVIDENCE, RI
ZIP 02903
Phone: (401) 444-5391
Fax: (401) 444-8918

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JAMES N. BUTERA M.D., an active Hematology & Oncology specialist practicing in Providence, RI. Our medical registry currently tracks 26 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,070 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 192 claims alone.


Allopurinol

Generic Formulation: AllopurinolSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 30.0
Days Supply 861
RI State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills109.4
Peer Average Days Supply3,251
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.2% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $123.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.71

State Avg Cost Per Claim

$17.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 468
RI State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.0
Peer Average Days Supply894
Conservative Utilization

This provider writes prescriptions for this formulation 41.4% less frequently than the standard regional baseline metric for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $218,377.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,845.74

State Avg Cost Per Claim

$14,250.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 37.4
Days Supply 898
RI State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.2
Peer Average Days Supply385
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $744.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.80

State Avg Cost Per Claim

$15.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 148
30-Day Fills 170.5
Days Supply 4,967
RI State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills127.8
Peer Average Days Supply3,495
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 59.1% higher than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $94,731.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$640.08

State Avg Cost Per Claim

$667.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
RI State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills109.8
Peer Average Days Supply3,178
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 85.9% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.79

State Avg Cost Per Claim

$20.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydroxychloroquine Sulfate

Generic Formulation: Hydroxychloroquine SulfateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 21.0
Days Supply 630
RI State Average Benchmarks
Peer Average Claims103.0
Peer Average 30-Day Fills185.9
Peer Average Days Supply5,517
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 88.3% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $267.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.29

State Avg Cost Per Claim

$83.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Therapeutic Applications

Hydroxychloroquine is used to prevent or treat malaria caused by mosquito bites. The United States Center for Disease Control provides updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs. This medication is also used to treat certain auto-immune diseases (lupus, rheumatoid arthritis). It belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs). It can reduce skin problems in lupus and prevent swelling/pain in arthritis. Hydroxychloroquine is not recommended for coronavirus infection, also known as COVID-19, unless you are enrolled in a study. Talk to your doctor about the risks and benefits.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 192
30-Day Fills 388.4
Days Supply 11,584
RI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills79.9
Peer Average Days Supply2,345
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 368.3% higher than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,524.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.98

State Avg Cost Per Claim

$39.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 56
30-Day Fills 56.0
Days Supply 1,660
RI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply692
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 154.5% higher than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29,265.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$522.60

State Avg Cost Per Claim

$1,616.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 700
RI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply643
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $358,950.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,358.00

State Avg Cost Per Claim

$13,875.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 358
RI State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply579
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $220,130.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,344.17

State Avg Cost Per Claim

$16,817.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 43
30-Day Fills 43.0
Days Supply 1,197
RI State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply476
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 152.9% higher than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $600,525.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,965.72

State Avg Cost Per Claim

$13,861.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 357
RI State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply184
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $109.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.31

State Avg Cost Per Claim

$9.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ninlaro

Generic Formulation: Ixazomib CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
RI State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.0
Peer Average Days Supply448
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $176,737.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,624.12

State Avg Cost Per Claim

$12,022.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (multiple myeloma). It works by slowing or stopping the growth of cancer cells.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 276
RI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.5
Peer Average Days Supply342
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $310.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.48

State Avg Cost Per Claim

$22.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 224
RI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills41.7
Peer Average Days Supply656
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.5% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $77.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.58

State Avg Cost Per Claim

$19.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 57
30-Day Fills 57.0
Days Supply 1,533
RI State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills35.2
Peer Average Days Supply967
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 62.9% higher than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,075,338.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,865.58

State Avg Cost Per Claim

$19,546.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Potassium Chloride

Generic Formulation: Potassium ChlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 24.0
Days Supply 686
RI State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills67.3
Peer Average Days Supply1,928
Conservative Utilization

This provider writes prescriptions for this formulation 48.7% less frequently than the standard regional baseline metric for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $484.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.22

State Avg Cost Per Claim

$32.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.

Therapeutic Applications

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 51
30-Day Fills 58.1
Days Supply 800
RI State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills55.4
Peer Average Days Supply1,006
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $211.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.14

State Avg Cost Per Claim

$5.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 68
30-Day Fills 68.0
Days Supply 1,904
RI State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills55.9
Peer Average Days Supply1,524
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,107,241.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,282.96

State Avg Cost Per Claim

$17,708.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Sprycel

Generic Formulation: DasatinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
RI State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.3
Peer Average Days Supply457
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $291,110.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,194.42

State Avg Cost Per Claim

$12,250.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.

Tasigna

Generic Formulation: Nilotinib HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
RI State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.5
Peer Average Days Supply378
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237,024.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,752.03

State Avg Cost Per Claim

$18,212.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Thalomid

Generic Formulation: ThalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 980
RI State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply722
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 40.0% more claims than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $228,750.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,535.73

State Avg Cost Per Claim

$6,922.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.

Therapeutic Applications

This medication is used to treat or prevent certain skin conditions related to Hansen's disease, once known as leprosy (erythema nodosum leprosum). Thalidomide is also used to treat a certain type of cancer (multiple myeloma). It works in Hansen's disease by reducing swelling and redness (inflammation). It also reduces the formation of blood vessels that feed tumors.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 71
30-Day Fills 136.7
Days Supply 4,032
RI State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply587
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 255.0% higher than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,720.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.32

State Avg Cost Per Claim

$37.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 46
30-Day Fills 46.0
Days Supply 1,211
RI State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.2
Peer Average Days Supply601
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 119.0% higher than the standard regional baseline profile for RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $476,544.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,359.67

State Avg Cost Per Claim

$11,044.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 51
30-Day Fills 63.0
Days Supply 1,890
RI State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills83.9
Peer Average Days Supply2,356
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $37,186.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$729.15

State Avg Cost Per Claim

$783.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Zydelig

Generic Formulation: IdelalisibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
RI State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.0
Peer Average Days Supply360
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $183,442.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,286.90

State Avg Cost Per Claim

$14,061.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (chronic lymphocytic leukemia-CLL). Idelalisib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JAMES N. BUTERA M.D. provides transparency into local medical care patterns within Providence, RI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.